PAD4 Inhibitor Screening Assay Kit (AMC) Reference: 701320-96 PAD4 is a guanidino-modifying enzyme that functions as a transcriptional coregulator catalyzing the conversion of specific arginine residues to citrulline. Substrates for PAD4 include histones H2A, H3, and H4. PAD4 autocitrullinates itself at several sites, inhibiting its enzymatic activity. PAD4 activity is increased in rheumatoid arthritis, producing an abundance of citrulline-containing proteins that generate an immune response resulting in production of autoantibodies that ultimately attack the host tissues. PAD4 has also been implicated in several other diseases including multiple sclerosis, Alzheimer's disease, glaucoma, and cancer. Cayman's PAD4 Inhibitor Screening Assay (AMC) provides a convenient, fluorescence-based method for screening human PAD4 inhibitors.
α-Ketoglutarate Fluorometric Detection Assay Kit Reference: 701350-96 Cayman’s α-KG Fluorometric Detection Assay provides a fluorescence-based method for quantifying α-KG in biological samples such as serum, plasma, urine, and tissue. It can also be utilized to determine intracellular and extracellular α-ketoglutarate concentrations in cell culture samples.
PAD2 Inhibitor Screening Assay Kit (AMC) Reference: 701390-96 PAD2 is a guanidino-modifying enzyme that catalyzes the conversion of specific arginine residues to citrulline in a calcium-dependent manner. This enzyme has been implicated in several diseases, including rheumatoid arthritis (RA), retinal degeneration, and certain cancers. PAD2 has been shown to modify vimentin, fibrinogen, and β/γ-actin. Extracellular levels of PAD2 are increased in the lungs of smokers, providing a link between smoking as a risk factor for RA and anti-citrullinated protein antibodies among RA patients. Cayman's PAD2 Inhibitor Screening Assay Kit (AMC) provides a convenient method for screening human PAD2 inhibitors.